Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
Status:
Completed
Trial end date:
2018-02-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9
inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL
cholesterol.